Review article · 2022 · Open access
Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept
Immune Network, 22(5), e37 · Published 1 October 2022 · DOI 10.4110/in.2022.22.e37
In brief
“Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept” is a 2022 review article by Sangwook Oh and Aimee S. Payne, published in Immune Network. OpenAlex counts 25 citations as of 20 November 2026, which puts it in the top 5% of works published in 2022 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Immune Network.
- Citations
- 25
- Most cited in
- 2024 (10)
- Field-weighted impact
- 0.60
- References
- 81
- Authors
- 2
Abstract
Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Oh, S., & Payne, A. S. (2022). Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept. Immune Network, 22(5), e37. https://doi.org/10.4110/in.2022.22.e37
MLA 9
Oh, Sangwook, and Aimee S. Payne. “Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept.” Immune Network, vol. 22, no. 5, 2022, p. e37. https://doi.org/10.4110/in.2022.22.e37.
Chicago
Oh, Sangwook and Aimee S. Payne. 2022. “Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept.” Immune Network 22 (5): e37. https://doi.org/10.4110/in.2022.22.e37.
Harvard
Oh, S. and Payne, A. S. (2022) ‘Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept’, Immune Network, 22(5), p. e37. doi:10.4110/in.2022.22.e37.
IEEE
S. Oh and A. S. Payne, “Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept,” Immune Network, vol. 22, no. 5, p. e37, 2022, doi: 10.4110/in.2022.22.e37.
BibTeX
@article{oh2022engineering,
title = {{Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept}},
author = {Oh, Sangwook and Payne, Aimee S.},
journal = {Immune Network},
year = {2022},
volume = {22},
number = {5},
pages = {e37},
doi = {10.4110/in.2022.22.e37},
url = {https://doi.org/10.4110/in.2022.22.e37}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 3 | |
| 2024 | 10 | |
| 2025 | 7 | |
| 2026 | 5 |
Its field-weighted citation impact is 0.60: it has been cited 0.60 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- autoimmune disease
- engineered cell therapy
- B-cell depletion
- B cell-mediated autoimmunity
- genetically modified T cells
- autoantibodies
- autoantigens
- clinical trials
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Oh, S., & Payne, A. S. (2022). Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept. Immune Network, 22(5), e37. https://doi.org/10.4110/in.2022.22.e37
How many times has this paper been cited?
25 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Immune Network: sign in and open the full text from this page.
Who wrote this paper?
Sangwook Oh, Aimee S. Payne.
What is the DOI of this paper?
10.4110/in.2022.22.e37, permanently at https://doi.org/10.4110/in.2022.22.e37. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.